We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 474

Federal court prohibits the approval of a generic prodrug CELLCEPT (mycophenolate mofetil)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 26 2011

On July 13, 2011, the Federal Court allowed an application by Hoffman La-Roche Limited (“Roche”), pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. (“Apotex”) in respect of its generic version of the drug mycophenolate mofetil (“MMF”) until after the expiry of Canadian Patent No. 1,333,285 (the “285 Patent”

Biosimilar battlegrounds - what is new in biosimilars and where?

  • Bereskin & Parr LLP
  • -
  • Canada, European Union, USA
  • -
  • February 17 2012

Biosimilars are second entry biologic drugs

The Myriad decision: what is the impact?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013

Health Canada and Federal Court make important biologic decisions

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • January 20 2014

Last week was a landmark for biologics in Canada: Health Canada approved two antibody subsequent entry biologics (SEBs) and the Federal Court issued a

Isolated human DNA molecules are patent eligible, cancer screening methods are not

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • August 17 2011

The United States Court of Appeals for the Federal Circuit on July 29, 2011 held in a split decision that isolated BRCA 12 DNA molecules patented and used by Myriad Genetics Inc. for diagnosing increased breast and ovarian cancer risk are patentable

Pharma in brief - Canada: Federal Court dismisses prohibition application for drospirenone YASMIN due to non-infringing process

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 15 2013

Bayer Inc. and Bayer Pharma Aktiengesellschaft (“Bayer”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Patented medicines (notice of compliance) listing update

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Listing a patent on the Patent Register maintained by the Minister of Health is the gateway through which an innovator gains access to the provisions

Supreme Court of Canada finds patented medicine prices review board has jurisdiction over price of thalomid in Canada

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • January 25 2011

The Supreme Court of Canada released a decision on January 20, 2011 in Celgene Corp. v. Canada (Attorney General), 2011 SCC 1 that may have a chilling effect on the availability of medicines under Health Canada’s Special Access Program (SAP

Sanofi’s Canadian patent on Plavix valid and infringed by Apotex

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • July 30 2013

On July 24, 2013 the Federal Court of Appeal released its decision reversing the trial court's ruling that Sanofi's patent covering Plavix is